Technology Platform-GOPATH
diagnostic services Pharma

Molecular Genetics & Genomics: Targeted Mutation Detection
GoPath offers a full suite of genetic and genomic assays. Targeted NGS panels and cancer-specific custom gene panels provide a comprehensive analysis of well-characterized cancer genes that include:
• Molecular Genomic Profiling from FFPE Tissue Samples          
• Sequencing of the Entire Coding Region          
• Analysis of Rearrangements          
• Microsatellite Instability Analysis (MSI)  
• Cutting-Edge Bioinformatics Pipeline
• Tumor Mutational Burden (TMB) and iScore
• Neoantigen Prediction
• Liquid Biopsy (ctDNA)
Flow Cytometry
• Immunophenotyping          
• Biomarker Analysis          

Proprietary Immunotherapy Biomarker Testing
• Multidimensional immunotherapy testing platform designed to classify immune-oncology biomarkers and to support cancer immunotherapy drug development
• Mutational Analysis that includes TMB and MSI analysis
• Immune gene expression analysis (IHC and proprietary RNA-seq panel to characterize the immune response) 
Immunohistochemistry (IHC) & Immunoflorescence (IF) 
• CLIA-validated IHC/IF assays, pharmDx IHC/IF assays and IHC-based companion diagnostics for immunotherapies
• Strong history of LDT and companion diagnostic development
• On-site pathologists assist with optimization and standardization of new IHC/IF targets
• Develops custom IHC/IF assays and offers solutions to optimize existing IHC/IF assays
• Comprehensive collection of IHC/IF assays
• Consistently incorporates new IHC/IF assays with rapid validation times
• Use of fluorescence in situ hybridization (FISH) panels including:
          •   ALL panel (Acute Lymphoblastic Leukemia)
          •   AML panel (Acute Myeloid Leukemia)
          •   CLL panel (Chronic Lymphocytic Leukemia)
          •   CML probe (Chronic Myeloid Leukemia)
          •   MDS panel (Myelodysplastic Syndrome)
          •   MM panel (Multiple Myeloma)
          •   MPN panel (Myeloproliferative Neoplasia)
          •   NHL panel (Non-Hodgkins Lymphoma)
          •   T-Cell panel (Leukemia/Lymphoma)
Cell Culture
• GoPath leverages cell-based assays and biomarker analysis in preclinical and translational Mechanism of  Action (MOA) studies
• We have a bank of more than 100 human tumor cell lines
• Cell Proliferation
• Cell Cycle Analysis
• Apoptosis/Senescence Assays
• Migration/Invasion Assays
• Combination Drug Studies
• Over-expression and knock-down studies